Valneva SE commenced rolling submission for initial approval of the company’s COVID-19 vaccine candidate VLA2001 with the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom.

Valneva SE announced the initiation of a further Phase 3 trial (VLA2001-304) for the company’s inactivated, adjuvanted Covid-19 vaccine candidate VLA2001.

As the world awaits the production and distribution of hundreds of millions of doses of COVID-19 vaccines that have been granted emergency use authorization, biopharmaceutical companies and manufacturers are developing the next wave of vaccines and therapeutics to combat the pandemic.